Get started
ASTRAZENECA DRNASTRAZENECA DRNASTRAZENECA DRN

ASTRAZENECA DRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

A1ZN34 trade ideas

BULLISH ON AZNAstraZeneca's Q3 2024 earnings exceeded expectations, with a revenue increase of 18%, signaling healthy demand for its products, especially in oncology and rare diseases. Technicals - Key Indicators: RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not yet in overbought territory, suggesting there’s still room for growth​ Trendline support: The stock is currently around the trendline support ​ STOCK ANALYSIS​ Support Levels: AZN’s stock is trading close to its key support levels, around $66.26, and has shown resilience above the $60 mark, which historically has been a strong support zone. The stock is likely to maintain upward pressure if it holds above this level​
NASDAQ:AZNLong
by ofoyekpene
Astrazeneca (Wait for correction to complete)Hello, To demonstrate how we can leverage TradingView for informed investment decisions, let’s analyze AstraZeneca as our example today. I will follow a structured approach and provide an investment recommendation based on both fundamental and technical insights. Understanding the Business Before making any investment decision, it's crucial to grasp the company's business model, revenue sources, and market standing. AstraZeneca is a global biopharmaceutical company known for its innovative research and development in key therapeutic areas, including: Oncology: AstraZeneca is a leading player in cancer research, with a robust portfolio of treatments for various types of cancer, contributing significantly to its revenue. Cardiovascular, Renal & Metabolism (CVRM): This segment includes treatments for conditions like diabetes and heart failure, reflecting the company’s diversified focus. Respiratory & Immunology: AstraZeneca has a strong foothold in respiratory medicines, providing therapies for asthma and COPD, which are critical in global healthcare. This diversified portfolio not only enhances revenue stability but also positions AstraZeneca well to navigate market fluctuations and emerging healthcare challenges. Financial Overview Examining AstraZeneca’s financial health is essential. The company has demonstrated steady revenue growth over recent years, supported by successful product launches and strategic acquisitions. The net income and earnings per share (EPS) have shown resilience, even amid challenging market conditions. The revenue has consistently grown since 2015, as seen in the historical financial charts. Net income trends and diluted EPS are also key indicators of the company's profitability and should be monitored closely. Technical Analysis Technical analysis reveals valuable insights into AstraZeneca's stock price movements. Over the past year, the stock has shown signs of a bullish trend, driven by strong company fundamentals and positive investor sentiment. Currently, AstraZeneca's stock is experiencing a correction phase, testing its key support levels. Will be looking for buy at USD 72 with USD 87 as the target. Best regards & good luck
NASDAQ:AZN
by thesharkke
2
AstraZeneca - GBP | Chart & Forecast SummaryKey Indicators on Trade Set Up in General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Active Sessions on Relevant Range & Elemented Probabilities; * Asian(Ranging) - London(Upwards) - NYC(Downwards) * Weekend Crypto Session Trend | Time Frame Conductive | Weekly Time Frame - General Trend - Measurement on Session * Support & Resistance * Trade Area | Focus & Motion Ahead # Position & Risk Reward | Daily Time Frame - Measurement on Session * Retracement | 0.5 & 0.618 * Extension | 0.88 & 1 Conclusion | Trade Plan Execution & Risk Management on Demand; Overall Consensus | Buy
CAPITALCOM:AZNL
by jasper16231
FTSE's Pharma Surge: A Closer Look at Leading StocksThe FTSE 100’s recent surge has been led by the pharmaceutical sector, marking a 13.7% increase in just the last month. Let’s delve into the standout performers that are leading the rally. AstraZeneca (AZN): +14.5% YTD AstraZeneca’s share price jumped higher following the release of a market-beating set of results… In the first quarter of 2024, AstraZeneca performed exceptionally well, surpassing analysts’ expectations with a 19% growth in revenue. This impressive growth was primarily driven by increased sales of its cancer drugs. The pharma giant reported a revenue of $12.7 billion, significantly outperforming consensus estimates, which had projected $11.9 billion. AstraZeneca also reiterated its guidance for the current year, expecting double-digit growth in both sales and earnings. On the price chart, the shares have now moved into a key area of resistance which represent the April 2023 all-time highs. Momentum traders will be watching closely for a break and close above this resistance as it could trigger AstraZeneca’s next trend leg higher. AZN Daily Candle Chart Past performance is not a reliable indicator of future results GlaxoSmithKline (GSK): +21.1% YTD Like AstraZeneca, GSK's share price has been buoyed by a strong set of first-quarter results… GSK’s recent trading statement showed improvements across various metrics, with revenue increasing by 10% to £7.4 billion and underlying operating profit rising by 27% to £2.4 billion, driven by robust growth in Vaccines and Speciality medicines. GSK's momentum from last year has continued into 2024, driven by strong financial performance and supported by excellence in research & development, which resulted in four major product approvals last year. Vaccines have emerged as a key growth driver, particularly with products like Shingrix and the recently approved RSV vaccine, Arexvy. The company's focus on HIV treatments and the shift towards long-acting innovation therapies has also contributed to growth in this segment. On the price chart, GSK is showing strong upwards momentum with the shares breaking above swing resistance at the start of this month. However, the July 2022 cluster of swing highs should provide some resistance in the coming weeks. GSK Daily Candle Chart Past performance is not a reliable indicator of future results Hikma Pharmaceuticals (HIK): +11.3% YTD Relative to AstraZeneca and GSK, Hikma has been a laggard with prices chopping sideways within a long-term wedge pattern (see chart below). That said, recent price action saw the shares print a large bullish reversal pattern following a market-beating trading statement… Hikma reported a 30% increase in profit, reaching $367 million last year, with revenue hitting $2.875 billion, up by 14% from the previous year. The core business saw operating profit up by 19%, mainly due to better profitability in both branded and generic segments. Generics experienced strong growth, with revenue up by 39% and core operating profit up by 86%. However, the company expects profits to be slightly lower in 2024 compared to last year. We are starting to see sector laggards like Hikma picking up momentum as the front runners, AZN and GSK move towards resistance. This indicates that the FTSE’s Pharma rally may be entering into the final phases. HIK Daily Candle Chart Past performance is not a reliable indicator of future results Disclaimer: This is for information and learning purposes only. The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance. Social media channels are not relevant for UK residents. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.84% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
LSE:AZN
by Capitalcom
AZN - BEARISH SCENARIOAstraZeneca's stock experienced a significant decline of over 4% on Monday due to uncertainties surrounding the future of CEO Pascal Soriot, as reported in the news. Initially, the company refrained from commenting on the report but later clarified that they do not engage in discussions regarding market rumors. Their shares, listed as NASDAQ: AZN, closed down 3.2%, marking the lowest point since July 19. Market analysts and a shareholder attributed this decline to the report, which indicated the possibility of Soriot leaving as soon as next year. Additionally, another article published on the same day discussed the retirement of Mene Pangalos, the long-time head of biopharmaceuticals research at AstraZeneca, although it appeared to present a contradictory view, quoting Pangalos as stating that Soriot had many productive years ahead of him. This supports potential competition of head and shoulder formation to the mid-50s range.
NASDAQ:AZNShort
by legacyFXofficial
1
AZN To Test Yearly Pivot Support AstraZeneca marginally eclipsed its prior cycle highs through the 72.00 level before pulling back to suggest a potential weekly double top pattern, however, I would highlight the lack of momentum divergence at this point, which suggests to me that the current retreat is corrective. On the four-hour time frame, we can clearly see an interim 5-wave sequence has been completed, I am now looking for a corrective cycle to unfold that ultimately tests and hold the yearly pivot point at the 64.00 area, from hear I will be looking for bullish reversal patterns to re-engage long exposure to target are retest and break of the prior cycle highs through 72.00 to challenge the weekly projected trend channel support towards the 76.00 level. A loss of the yearly pivot support on a daily closing basis would suggest a deeper correction is likely to unfold opening a test of the weekly high-volume node and projected trend channel support at the 55/56.00 area.
NASDAQ:AZN
by Tickmill